查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930032

乾癬治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2025-2034）

Psoriasis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 166 Pages | 商品交期: 請詢問到貨日

價格

乾癬治療市場成長因素

預計2025年全球乾癬治療市場規模將達291.5億美元，2026年成長至314.2億美元，到2034年將達到729.9億美元。市場成長的驅動因素包括疾病盛行率上升、生物療法應用日益廣泛、公眾意識提升活動不斷擴大以及強大的臨床研發管線。2025年，北美將以74.83%的市場佔有率佔據主導地位，這主要得益於生物製劑的高使用率、廣泛的保險覆蓋率以及強有力的監管審批。

乾癬是一種慢性自體免疫發炎性疾病，其特徵是皮膚細胞快速增生、斑塊形成、發炎、以及乾癬性關節炎引起的關節受累。約30-40%的乾癬患者會發展為乾癬關節炎，增加了長期治療的需求。斑塊型乾癬仍然是最常見的類型，佔所有病例的80-90%，因此對長期藥物治療的需求持續存在。

市場驅動因素

銀屑病患病率的不斷上升是主要驅動因素。據估計，全球約有2-3%的人口患有乾癬，這推動了對有效全身和局部治療的需求。各國政府和醫療機構努力促進早期診斷和提高公眾對銀屑病的認識，提高治療啟動率。

另一個主要驅動因素是針對發炎細胞因子的生物製劑研發管線實力雄厚。 IL-17、IL-23 和 TYK2 抑制劑的監管批准改善了臨床療效，並增強了醫生對生物製劑處方的信心。針對兒童和乾癬性關節炎患者的適應症擴大，進一步增加了患者的治療選擇。

市場趨勢

一個關鍵趨勢是，生物製劑正朝著目標特定免疫路徑、安全性和有效性更高的方向發展。與傳統療法相比，生物製劑具有更高的緩解率、更長的緩解持續時間和更低的全身性毒性。製造商大力投資下一代生物製劑和生物相似藥，以提高其可負擔性和市場准入。

遠距皮膚科會診的引進也改善了病患監測和處方連續性，有助於提高長期用藥依從性，尤其是在農村地區和公共衛生緊急情況下。

市場限制因子

高昂的治療費用仍然是一個重大障礙，尤其是在發展中國家。生物製劑的生產成本高昂，會增加病患的自付費用。有限的償付限制了低收入者對生物製劑的使用，導致治療啟動延遲和市場滲透率低。

儘管局部用藥和全身用藥等替代療法具有成本效益，但它們通常無法提供生物製劑所能提供的長期疾病控制，導致區域間藥物可及性差異。

市場區隔分析

依藥物類別

市場細分為TNF抑制劑、白血球介素抑制劑和其他藥物。預計到2026年，TNF抑制劑將佔據市場主導地位，市場佔有率達到41.31%，主要得益於其悠久的臨床應用歷史和生物相似藥的普及。然而，由於白細胞介素抑制劑具有卓越的療效、更高的安全性以及不斷擴大的臨床試驗計畫，因此預計其成長速度將最快。

依類型劃分

依類型劃分，市場包括斑塊狀乾癬、乾癬關節炎和其他疾病。2026年，斑塊狀乾癬將佔市場佔有率的41.31%，這主要得益於其高發病率和龐大的患者群體。銀屑病關節炎市場正經歷快速成長，這主要歸功於診斷率的提高和生物製劑的廣泛應用。

依產品類型劃分

依產品類型劃分，市場分為生物製劑和非生物製劑。2026年，生物製劑將佔市場佔有率的90.73%，這充分反映了IL-17和IL-23抑制劑等標靶療法的廣泛應用。由於口服藥物的核准以及其低成本帶來的高可及性，非生物製劑市場持續成長。

依給藥途徑

市場分為口服、腸外/全身給藥及局部給藥。2026年，腸外/全身給藥佔83.48%的市場佔有率，這主要得益於生物製劑注射和輸注給藥的廣泛應用。口服給藥因其便利性和TYK2抑制劑獲批數量的增加而不斷擴大。

依通路

通路包括醫院藥房、零售藥房和線上藥房。2024年，零售藥局憑藉其廣泛的覆蓋範圍和便利的處方續藥服務佔據主導地位，而線上藥局則透過送貨上門服務和生物相似藥合作迅速擴張。

區域展望

2025年，北美市場規模達到218.1億美元，主要得益於先進生物製劑的引進及完善的醫保償付系統。受FDA批准和聯邦醫療保險（Medicare）價格談判的推動，美國市場預計到2026年將達到217.5億美元。

歐洲市場需求強勁，預計到2026年，德國市場規模將達到10.5億美元，英國將達到6.3億美元，這主要得益於監管部門的批准和完善的醫療保險體系。亞太地區是成長最快的地區，預計到2026年，中國市場規模將達到7.4億美元，日本將達到6.1億美元，印度將達到2.7億美元，這主要得益於臨床試驗的擴展和政府的宣傳推廣活動。拉丁美洲和中東及非洲地區正透過擴大醫療保健服務覆蓋範圍和提高疾病認知度而實現成長。

本報告分析了2025年、2026年和2034年的市場規模和價值，並依藥物類別、類型、產品類型、給藥途徑和通路進行了細分。報告還包括區域和國家特定的市場價值、監管動態、產品上市、臨床研發管線進展以及影響全球銀屑病治療行業的競爭策略。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 2025年主要全國乾癬率
  • 主要國家/地區監管和償付狀況概述
  • 主要公司新產品發布
  • 主要公司產品線分析
  • 主要公司主要產業趨勢
  • 新冠疫情對市場的影響

章節5：全球乾癬治療市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測 - 依藥物類別劃分
    • TNF抑制劑
    • 白血球介素抑制劑
    • 其他
  • 市場分析、洞察與預測 - 依類型劃分
    • 斑塊狀乾癬
    • 乾癬關節炎
    • 其他
  • 市場分析、洞察與預測 - 依產品類型劃分
    • 生物製品
    • 非生物製品
  • 市場分析、洞察與預測 - 依給藥途徑劃分
    • 口服
    • 注射/全身給藥
    • 外用
  • 市場分析、洞察與預測 - 依通路劃分通路
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美乾癬治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲乾癬治療市場分析、洞察與預測（2021-2034）

  • 依國家/地區
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 歐洲其他地區

第8章 亞太地區乾癬治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳洲和紐西蘭
    • 亞太其他地區

第9章 拉丁美洲乾癬治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家國家/地區

第10章 中東和非洲乾癬治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • GCC
    • 南非
    • 其他中東和非洲國家/地區

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • AbbVie Inc.
    • Novartis AG
    • Johnson &Johnson Services, Inc.
    • Pfizer Inc.
    • LEO Pharma A/S
    • Merck &Co., Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Evelo Biosciences, Inc.
    • UCB S.A.
    • Sun Pharmaceutical Industries Ltd.
Product Code: FBI100600

Growth Factors of psoriasis treatment Market

The global psoriasis treatment market size was valued at USD 29.15 billion in 2025 and is projected to grow to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034. Market growth is supported by rising disease prevalence, increasing adoption of biologic therapies, expanding awareness programs, and strong clinical development pipelines. In 2025, North America dominated the market with a share of 74.83%, driven by high biologic usage, extensive insurance coverage, and robust regulatory approvals.

Psoriasis is a chronic autoimmune inflammatory disorder characterized by rapid skin cell proliferation, plaque formation, inflammation, and joint involvement in psoriatic arthritis. Approximately 30%-40% of psoriasis patients develop psoriatic arthritis, increasing long-term therapy needs. Plaque psoriasis remains the most common form, accounting for 80%-90% of total cases, creating sustained demand for long-term pharmacologic management.

Market Drivers

The growing prevalence of psoriasis remains a primary driver. An estimated 2%-3% of the global population suffers from psoriasis, increasing demand for effective systemic and topical therapies. Governments and healthcare organizations are promoting early diagnosis and disease awareness, improving treatment initiation rates.

Another major driver is the strong pipeline of biologic drugs targeting inflammatory cytokines. Regulatory approvals for IL-17, IL-23, and TYK2 inhibitors are improving clinical outcomes and increasing physician confidence in biologic prescribing. Expanded indications for pediatric and psoriatic arthritis populations further increase patient eligibility.

Market Trends

A dominant trend is the shift toward biologic therapies that target specific immune pathways with improved safety and efficacy. Biologics offer higher clearance rates, longer remission periods, and reduced systemic toxicity compared to conventional therapies. Manufacturers are investing heavily in next-generation biologics and biosimilars to improve affordability and expand market access.

Teledermatology adoption is also improving patient monitoring and prescription continuity, particularly in rural regions and during public health emergencies, supporting long-term medication adherence.

Market Restraints

High treatment costs remain a significant barrier, especially in developing countries. Biologic therapies involve high manufacturing expenses, leading to elevated out-of-pocket costs for patients. Limited reimbursement frameworks restrict biologic adoption in low-income populations, delaying therapy initiation and reducing market penetration.

Topical and systemic alternatives remain cost-effective but often lack the long-term disease control achieved by biologics, creating access disparities across regions.

Segmentation Analysis

By Drug Class

The market is segmented into TNF inhibitors, interleukin inhibitors, and others. TNF inhibitors dominated with 41.31% market share in 2026, driven by long-established clinical usage and biosimilar availability. However, interleukin inhibitors are registering the fastest growth due to superior efficacy, improved safety profiles, and expanding clinical trial programs.

By Type

By type, the market includes plaque psoriasis, psoriatic arthritis, and others. Plaque psoriasis accounted for 41.31% market share in 2026, driven by high disease prevalence and large patient populations. Psoriatic arthritis is experiencing rapid growth due to improved diagnostic rates and expanded biologic indications.

By Product Type

Based on product type, the market is segmented into biologics and non-biologics. Biologics dominated with 90.73% share in 2026, reflecting strong adoption of targeted therapies such as IL-17 and IL-23 inhibitors. Non-biologics continue to grow due to oral drug approvals and lower cost accessibility.

By Route of Administration

The market is categorized into oral, parenteral/systemic, and topical. Parenteral/systemic therapies accounted for 83.48% share in 2026, supported by widespread biologic administration through injections and infusions. Oral therapies are expanding due to convenience and increasing TYK2 inhibitor approvals.

By Distribution Channel

Distribution includes hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies dominated in 2024 due to wide accessibility and refill convenience, while online pharmacies are expanding rapidly through home delivery services and biosimilar partnerships.

Regional Outlook

North America generated USD 21.81 billion in 2025, supported by advanced biologic adoption and strong reimbursement systems. The U.S. market reached USD 21.75 billion in 2026, driven by FDA approvals and Medicare pricing negotiations.

Europe holds strong demand, with Germany valued at USD 1.05 billion and the U.K. at USD 0.63 billion in 2026, supported by regulatory approvals and national healthcare coverage. Asia Pacific is the fastest-growing region, with China at USD 0.74 billion, Japan at USD 0.61 billion, and India at USD 0.27 billion in 2026, driven by clinical trial expansion and government awareness programs. Latin America and Middle East & Africa are growing through expanding healthcare access and disease awareness.

Competitive Landscape

Key players include AbbVie, Johnson & Johnson, Novartis, Pfizer, Eli Lilly, Amgen, LEO Pharma, UCB, and Sun Pharmaceutical Industries. Market leaders focus on biologic innovation, biosimilar expansion, and multi-indication labeling strategies. Strategic acquisitions and global clinical programs strengthen product pipelines and market coverage.

Report Coverage

The report analyzes market size and value for 2025, 2026, and 2034, with segmentation by drug class, type, product type, route of administration, and distribution channel. It includes regional and country-level market values, regulatory trends, product launches, clinical pipeline developments, and competitive strategies shaping the global psoriasis treatment industry.

Conclusion

The psoriasis treatment market is expanding from USD 29.15 billion in 2025 to USD 31.42 billion in 2026, reaching USD 72.99 billion by 2034, driven by rising disease burden, biologic therapy innovation, and expanding global treatment access. Dominance of biologics, strong performance of parenteral therapies, and leadership by North America reflect advanced treatment adoption, while rapid growth in Asia Pacific highlights increasing healthcare investment and regulatory support. Continued innovation in immune-targeted therapies, biosimilars, and oral treatment options is strengthening long-term market sustainability across diverse patient populations.

Segmentation By Drug Class

  • TNF Inhibitors
  • Interleukins Inhibitors
  • Others

By Type

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

By Product Type

  • Biologics
  • Non-Biologics

By Route of Administration

  • Oral
  • Parenteral/Systemic
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country)
    • U.S. (By Type)
    • Canada (By Type)
  • Europe (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K. (By Type)
    • Germany (By Type)
    • France (By Type)
    • Italy (By Type)
    • Spain (By Type)
    • Scandinavia (By Type)
    • Rest of Europe (By Type)
  • Asia Pacific (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan (By Type)
    • China (By Type)
    • India (By Type)
    • Australia & New Zealand (By Type)
    • Rest of Asia Pacific (By Type)
  • Latin America (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil (By Type)
    • Mexico (By Type)
    • Rest of Latin America (By Type)
  • Middle East & Africa (By Drug Class, Type, Product Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC (By Type)
    • South Africa (By Type)
    • Rest of the Middle East & Africa (By Type)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Psoriasis, By Key Countries, 2025
  • 4.2. Overview: Regulatory Scenario & Reimbursement Scenario, By Key Countries/Region
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments, By Key Players
  • 4.6. Impact of COVID-19 on the Market

5. Global Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. TNF Inhibitors
    • 5.1.2. Interleukins Inhibitors
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Plaque Psoriasis
    • 5.2.2. Psoriatic Arthritis
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Product Type
    • 5.3.1. Biologics
    • 5.3.2. Non-Biologics
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Oral
    • 5.4.2. Parenteral/Systemic
    • 5.4.3. Topical
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. TNF Inhibitors
    • 6.1.2. Interleukins Inhibitors
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Plaque Psoriasis
    • 6.2.2. Psoriatic Arthritis
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Product Type
    • 6.3.1. Biologics
    • 6.3.2. Non-Biologics
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Oral
    • 6.4.2. Parenteral/Systemic
    • 6.4.3. Topical
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
      • 6.6.1.1. By Type
    • 6.6.2. Canada
      • 6.6.2.1. By Type

7. Europe Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. TNF Inhibitors
    • 7.1.2. Interleukins Inhibitors
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Plaque Psoriasis
    • 7.2.2. Psoriatic Arthritis
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Product Type
    • 7.3.1. Biologics
    • 7.3.2. Non-Biologics
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Oral
    • 7.4.2. Parenteral/Systemic
    • 7.4.3. Topical
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K
      • 7.6.1.1. By Type
    • 7.6.2. Germany
      • 7.6.2.1. By Type
    • 7.6.3. France
      • 7.6.3.1. By Type
    • 7.6.4. Spain
      • 7.6.4.1. By Type
    • 7.6.5. Italy
      • 7.6.5.1. By Type
    • 7.6.6. Scandinavia
      • 7.6.6.1. By Type
    • 7.6.7. Rest of Europe
      • 7.6.7.1. By Type

8. Asia Pacific Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. TNF Inhibitors
    • 8.1.2. Interleukins Inhibitors
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Plaque Psoriasis
    • 8.2.2. Psoriatic Arthritis
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Product Type
    • 8.3.1. Biologics
    • 8.3.2. Non-Biologics
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Oral
    • 8.4.2. Parenteral/Systemic
    • 8.4.3. Topical
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
      • 8.6.1.1. By Type
    • 8.6.2. China
      • 8.6.2.1. By Type
    • 8.6.3. India
      • 8.6.3.1. By Type
    • 8.6.4. Australia & New Zealand
      • 8.6.4.1. By Type
    • 8.6.5. Rest of Asia Pacific
      • 8.6.5.1. By Type

9. Latin America Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. TNF Inhibitors
    • 9.1.2. Interleukins Inhibitors
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Plaque Psoriasis
    • 9.2.2. Psoriatic Arthritis
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Product Type
    • 9.3.1. Biologics
    • 9.3.2. Non-Biologics
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Oral
    • 9.4.2. Parenteral/Systemic
    • 9.4.3. Topical
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
      • 9.6.1.1. By Type
    • 9.6.2. Mexico
      • 9.6.2.1. By Type
    • 9.6.3. Rest of Latin America
      • 9.6.3.1. By Type

10. Middle East & Africa Psoriasis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. TNF Inhibitors
    • 10.1.2. Interleukins Inhibitors
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Plaque Psoriasis
    • 10.2.2. Psoriatic Arthritis
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Product Type
    • 10.3.1. Biologics
    • 10.3.2. Non-Biologics
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Oral
    • 10.4.2. Parenteral/Systemic
    • 10.4.3. Topical
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
      • 10.6.1.1. By Type
    • 10.6.2. South Africa
      • 10.6.2.1. By Type
    • 10.6.3. Rest of Middle East & Africa
      • 10.6.3.1. By Type

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Novartis AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Pfizer Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. LEO Pharma A/S
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Amgen Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Eli Lilly and Company
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Evelo Biosciences, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. UCB S.A.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Sun Pharmaceutical Industries Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 3: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 4: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 5: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Psoriasis Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 9: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 10: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Canada Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 15: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 18: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Germany Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: France Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 24: Italy Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 25: Spain Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Scandinavia Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Rest of Europe Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 28: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 29: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 30: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 31: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 32: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 33: Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 34: China Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 35: India Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 36: Japan Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 37: Australia & New Zealand Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 38: Rest of Asia Pacific Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 39: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 40: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 41: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 42: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 43: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 44: Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 45: Brazil Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 46: Mexico Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 47: Rest of Latin America Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 48: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 49: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 50: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 51: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 52: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 53: Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 54: GCC Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 55: South Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 56: Rest of Middle East & Africa Psoriasis Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034

List of Figures

  • Figure 1: Global Psoriasis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Psoriasis Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Psoriasis Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Psoriasis Treatment Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 5: Global Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Psoriasis Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 11: North America Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 12: North America Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 13: North America Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 14: North America Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 15: North America Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 16: North America Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Psoriasis Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Psoriasis Treatment Market Value Share (%), By Country, 2025
  • Figure 20: Europe Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Europe Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 24: Europe Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 25: Europe Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 26: Europe Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 27: Europe Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 28: Europe Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 35: Asia Pacific Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 36: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 37: Asia Pacific Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 38: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 40: Asia Pacific Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 47: Latin America Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 48: Latin America Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 49: Latin America Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 50: Latin America Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 51: Latin America Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Latin America Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 59: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Type, 2025
  • Figure 60: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 61: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Product Type, 2025
  • Figure 62: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Psoriasis Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Psoriasis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Psoriasis Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Psoriasis Treatment Market Share (%), By Company, 2025